DelveInsight’s report, “Chronic Pain Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of chronic pain. It covers historical and projected epidemiology and highlights market trends across key regions, including the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
To Know in detail about the Chronic Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Pain Market Forecast
Some of the key facts of the Chronic Pain Market Report:
-
The Chronic Pain market is projected to expand at a significant CAGR between 2020 and 2034. According to the International Association for the Study of Pain (IASP), pain is defined as an unpleasant sensory and emotional experience linked to actual or potential tissue damage, which may result from injury or misprocessing of pain signals by the brain. Chronic pain, persisting for more than three months, often requires long-term management and can vary from mild to severe.
-
In the EU4 and the UK, the UK reported the highest prevalence of chronic pain, accounting for roughly 30% of cases. Prevalence rises with age and is most common in individuals aged 45–64 years. In the United States in 2023, approximately 70% of chronic pain cases were classified as moderate to severe.
-
Chronic pain arises from various causes, including low back pain, musculoskeletal pain, migraines, fibromyalgia, neuralgia, cancer pain, visceral pain, and post-operative pain, though some cases have no identifiable origin. Market growth is expected to be driven by increased adoption of existing treatments, the introduction of novel therapies, and heightened awareness. The United States leads the market in size, followed by the EU4, the UK, and Japan.
-
Treatment options encompass a range of medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, opioid-like agents, combinations of opioids and non-narcotic analgesics, corticosteroids, antirheumatics/immunological agents, and anticonvulsants. Approved therapies include EMGALITY (galcanezumab-gnlm), TARLIGE (mirogabalin besylate), AIMOVIG (erenumab-aooe), AJOVY (fremanezumab), VYEPTI (eptinezumab), and PENNSAID Gel.
-
Opioids have traditionally been a primary treatment for moderate to severe pain, with around 168 million prescriptions written in the U.S. in 2018. Although the national opioid dispensing rate declined between 2012 and 2019, it remained high in 2019, at approximately 46.7 prescriptions per 100 people (over 153 million prescriptions). Opioids continue to be used in 40–50% of moderate to severe chronic pain cases in the U.S.
-
In 2023, the U.S. reported the highest prevalence of chronic pain among the seven major markets (7MM), followed by Japan and the UK.
-
Key Companies: AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others.
-
Key Therapies: JOYCLU (diclofenac etalhyaluronate sodium), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), ZILOSUL (pentosan polysulfate sodium), TNX-102 SL, and others.
-
The Chronic Pain market is expected to grow substantially due to rising prevalence and awareness, and the introduction of multiple late-stage pipeline therapies is anticipated to significantly reshape market dynamics during the forecast period.
Chronic Pain Overview
Chronic pain persisting for more than three months can become a serious clinical concern, often arising when acute pain is not adequately treated. Ongoing acute pain may lead to sensitization, causing structural and functional changes in the peripheral or central nervous system. This process lowers the pain threshold, increases neural excitability, and amplifies pain responses, ultimately transforming acute pain into chronic pain.
Chronic pain is generally diagnosed after 3–6 months of continuous symptoms, though diagnosis can be challenging. Assessment methods depend on the pain’s location, underlying cause, and associated symptoms, and may include blood tests, imaging techniques such as X-rays, MRIs for soft tissue and inflammation, CT scans for detailed evaluation, and nerve function tests.
Combination therapies, incorporating both pharmacological and non-pharmacological approaches, are often more effective than single-modality treatments. Pharmacological interventions are typically introduced gradually in a stepwise manner. Chronic pain patients frequently experience comorbid depression and anxiety and face a higher risk of suicide. The condition profoundly impacts all aspects of a patient’s life, making accurate diagnosis and tailored management critical for improving outcomes.
Get a Free sample for the Chronic Pain Market Forecast, Size & Share Analysis Report
Chronic Pain Epidemiology
The epidemiology section offers a comprehensive overview of past, present, and projected trends in the seven major markets (7MM) from 2020 to 2034. It examines the factors driving these trends by analyzing multiple studies and expert opinions. Additionally, this section provides an in-depth assessment of the diagnosed patient population and anticipated future developments.
Chronic Pain Epidemiology Segmentation:
The Chronic Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Diagnosed Prevalence of Chronic Pain in Adults
-
Diagnosed Prevalence of Chronic Pain in Pediatrics
-
Diagnosed Prevalence of Chronic Pain by Types
-
Diagnosed Prevalence of Chronic Pain by Location
-
Diagnosed Prevalence of Chronic Pain by Severity
Download the report to understand which factors are driving Chronic Pain epidemiology trends @ Chronic Pain Epidemiology Forecast
Chronic Pain Marketed Drugs: JOYCLU (diclofenac etalhyaluronate sodium): Seikagaku Corporation/Chiltern International
-
ZILRETTA (triamcinolone acetonide extended-release injectable suspension): Pacira BioSciences
Chronic Pain Emerging Drugs: ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals.
-
TNX-102 SL: Tonix Pharmaceuticals
Chronic Pain Therapies: JOYCLU (diclofenac etalhyaluronate sodium), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), ZILOSUL (pentosan polysulfate sodium), TNX-102 SL, and others
Chronic Pain Key Companies: AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others
Discover more about therapies set to grab major Chronic Pain market share @ Chronic Pain Treatment Landscape
Chronic Pain Market Outlook
Key players in the chronic pain sector, including Paradigm Biopharmaceuticals, Centrexion Therapeutics, and Tonix Pharmaceuticals, are progressing their leading drug candidates through various stages of clinical development, focusing on innovative treatment options for chronic pain. DelveInsight’s analysis indicates that market growth is likely to be driven by rising prevalence, increased awareness and accessibility of treatments, the development of non-opioid alternatives, holistic care approaches, organizational initiatives, and the growing elderly population.
In 2023, opioids continued to be the mainstay therapy for moderate to severe pain. Nonetheless, the expansion of the chronic pain drug market may be hindered by challenges such as diagnostic complexities, the absence of reliable biomarkers, the substantial impact of chronic pain on quality of life, opioid misuse and addiction concerns, and the economic burden associated with the condition. Within the EU4 and the UK, the United Kingdom accounted for the largest portion of the chronic pain market in 2023, at around 29%, followed by Germany.
Scope of the Chronic Pain Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Chronic Pain Companies: AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others
-
Key Chronic Pain Therapies: JOYCLU (diclofenac etalhyaluronate sodium), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), ZILOSUL (pentosan polysulfate sodium), TNX-102 SL, and others
-
Chronic Pain Therapeutic Assessment: Chronic Pain current marketed and Chronic Pain emerging therapies
-
Chronic Pain Market Dynamics: Chronic Pain market drivers and Chronic Pain market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Chronic Pain Unmet Needs, KOL’s views, Analyst’s views, Chronic Pain Market Access and Reimbursement
To know more about Chronic Pain companies working in the treatment market, visit @ Chronic Pain Clinical Trials and Therapeutic Assessment
Table of Contents
1. Chronic Pain Market Report Introduction
2. Executive Summary for Chronic Pain
3. SWOT analysis of Chronic Pain
4. Chronic Pain Patient Share (%) Overview at a Glance
5. Chronic Pain Market Overview at a Glance
6. Chronic Pain Disease Background and Overview
7. Chronic Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Pain
9. Chronic Pain Current Treatment and Medical Practices
10. Chronic Pain Unmet Needs
11. Chronic Pain Emerging Therapies
12. Chronic Pain Market Outlook
13. Country-Wise Chronic Pain Market Analysis (2020–2034)
14. Chronic Pain Market Access and Reimbursement of Therapies
15. Chronic Pain Market Drivers
16. Chronic Pain Market Barriers
17. Chronic Pain Appendix
18. Chronic Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Chronic Pain Pipeline
“Chronic Pain Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Pain market. A detailed picture of the Chronic Pain pipeline landscape is provided, which includes the disease overview and Chronic Pain treatment guidelines.
Chronic Pain Epidemiology
DelveInsight’s ‘Chronic Pain Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Chronic Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/